These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32420049)

  • 1. Combating COVID-19 with mesenchymal stem cell therapy.
    Rajarshi K; Chatterjee A; Ray S
    Biotechnol Rep (Amst); 2020 Jun; 26():e00467. PubMed ID: 32420049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19.
    Chaudhary JK; Saini D; Chaudhary PK; Maurya A; Verma GK; Gupta AK; Roshan R; Vats TK; Garg N; Yadav D; Kant N; Meena AK; Mirza-Shariff AA
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.
    Beirag N; Kumar C; Madan T; Shamji MH; Bulla R; Mitchell D; Murugaiah V; Neto MM; Temperton N; Idicula-Thomas S; Varghese PM; Kishore U
    Front Immunol; 2022; 13():960733. PubMed ID: 35967323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension.
    Saha S; Chakrabarti S; Singh PK; Poddar J; Satapathi S; Saini S; Kakar SS; Roy P
    Stem Cell Rev Rep; 2021 Feb; 17(1):132-143. PubMed ID: 32748331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Clinical Application of Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients: Review.
    Adugna DG
    Stem Cells Cloning; 2021; 14():71-80. PubMed ID: 34785907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
    Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
    Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells.
    Generali M; Kehl D; Wanner D; Okoniewski MJ; Hoerstrup SP; Cinelli P
    J Cell Mol Med; 2022 Jan; 26(1):228-234. PubMed ID: 34821008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
    Fu L; Gilham D; Stotz SC; Sarsons CD; Rakai BD; Tsujikawa LM; Wasiak S; Johansson JO; Sweeney M; Wong NCW; Kulikowski E
    Int Immunopharmacol; 2023 Apr; 117():109929. PubMed ID: 36857935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Proinflammatory Molecules and Tissue Factor by SARS-CoV-2 Spike Protein in Human Placental Cells: Implications for SARS-CoV-2 Pathogenesis in Pregnant Women.
    Guo X; Semerci N; De Assis V; Kayisli UA; Schatz F; Steffensen TS; Guzeloglu-Kayisli O; Lockwood CJ
    Front Immunol; 2022; 13():876555. PubMed ID: 35464466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients.
    Heidari F; Heidari R; Sabet MN; Hamidieh AA; Saltanatpour Z
    Curr Stem Cell Res Ther; 2024; 19(5):644-652. PubMed ID: 37073149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs in the development of potential therapeutic targets against COVID-19: A narrative review.
    Ahmed JQ; Maulud SQ; Dhawan M; Priyanka ; Choudhary OP; Jalal PJ; Ali RK; Tayib GA; Hasan DA
    J Infect Public Health; 2022 Jul; 15(7):788-799. PubMed ID: 35751930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
    Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells.
    Verma D; Church TM; Swaminathan S
    J Virol; 2021 Jun; 95(13):e0019221. PubMed ID: 33853968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.
    Hejenkowska ED; Mitash N; Donovan JE; Chandra A; Bertrand C; De Santi C; Greene CM; Mu F; Swiatecka-Urban A
    J Innate Immun; 2023; 15(1):629-646. PubMed ID: 37579743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.
    Chouw A; Milanda T; Sartika CR; Kirana MN; Halim D; Faried A
    Regen Eng Transl Med; 2022; 8(1):43-54. PubMed ID: 33723519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.
    Pantazi I; Al-Qahtani AA; Alhamlan FS; Alothaid H; Matou-Nasri S; Sourvinos G; Vergadi E; Tsatsanis C
    Front Immunol; 2021; 12():683800. PubMed ID: 34248968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
    Ahmed F
    Front Immunol; 2020; 11():590459. PubMed ID: 33362771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45
    Ratajczak MZ; Bujko K; Ciechanowicz A; Sielatycka K; Cymer M; Marlicz W; Kucia M
    Stem Cell Rev Rep; 2021 Feb; 17(1):266-277. PubMed ID: 32691370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety consideration of mesenchymal stem cell therapy on COVID-19.
    Cao Y; Wu H; Zhai W; Wang Y; Li M; Li M; Yang L; Tian Y; Song Y; Li J; Wang Y; Ding Q; Zhang L; Cai M; Chang Z
    Stem Cell Res; 2020 Dec; 49():102066. PubMed ID: 33242791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.